C. Kent Osborne
Breast Center at Baylor College of Medicine
1 Baylor Plaza
MS 600
Houston
USA
Name/email consistency: high
- Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Osborne, C.K., Shou, J., Massarweh, S., Schiff, R. Clin. Cancer Res. (2005)
- Estrogen-receptor biology: continuing progress and therapeutic implications. Osborne, C.K., Schiff, R. J. Clin. Oncol. (2005)
- Aromatase inhibitors: future directions. Osborne, C.K., Schiff, R. J. Steroid Biochem. Mol. Biol. (2005)
- Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Osborne, C.K., Bardou, V., Hopp, T.A., Chamness, G.C., Hilsenbeck, S.G., Fuqua, S.A., Wong, J., Allred, D.C., Clark, G.M., Schiff, R. J. Natl. Cancer Inst. (2003)
- Role of molecular and genetic markers in breast cancer treatment decisions. Osborne, C.K., Arteaga, C.L. J. Clin. Oncol. (2003)
- Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. Osborne, C.K., Pippen, J., Jones, S.E., Parker, L.M., Ellis, M., Come, S., Gertler, S.Z., May, J.T., Burton, G., Dimery, I., Webster, A., Morris, C., Elledge, R., Buzdar, A. J. Clin. Oncol. (2002)
- Estrogen receptor: current understanding of its activation and modulation. Osborne, C.K., Schiff, R., Fuqua, S.A., Shou, J. Clin. Cancer Res. (2001)